208 related articles for article (PubMed ID: 35031563)
1. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
Liao Y; Chen CH; Xiao T; de la Peña Avalos B; Dray EV; Cai C; Gao S; Shah N; Zhang Z; Feit A; Xue P; Liu Z; Yang M; Lee JH; Xu H; Li W; Mei S; Pierre RS; Shu S; Fei T; Duarte M; Zhao J; Bradner JE; Polyak K; Kantoff PW; Long H; Balk SP; Liu XS; Brown M; Xu K
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35031563
[TBL] [Abstract][Full Text] [Related]
2. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
4. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
8. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
9. Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.
Coulter JB; Easwaran H
PLoS Biol; 2023 Apr; 21(4):e3002081. PubMed ID: 37104249
[TBL] [Abstract][Full Text] [Related]
10. DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
Li Z; Li B; Yu H; Wang P; Wang W; Hou P; Li M; Chu S; Zheng J; Mao L; Bai J
Oncogene; 2022 Aug; 41(33):3991-4002. PubMed ID: 35804015
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
12. Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC.
Schade AE; Kuzmickas R; Rodriguez CL; Mattioli K; Enos M; Gardner A; Cichowski K
PLoS Biol; 2023 Apr; 21(4):e3002038. PubMed ID: 37104245
[TBL] [Abstract][Full Text] [Related]
13. Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.
Forma E; Jóźwiak P; Ciesielski P; Zaczek A; Starska K; Bryś M; Krześlak A
PLoS One; 2018; 13(6):e0198351. PubMed ID: 29864144
[TBL] [Abstract][Full Text] [Related]
14. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
[TBL] [Abstract][Full Text] [Related]
16. The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids.
Yang Q; Nair S; Laknaur A; Ismail N; Diamond MP; Al-Hendy A
Biol Reprod; 2016 Mar; 94(3):69. PubMed ID: 26888970
[TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.
Xu H; Xu K; He HH; Zang C; Chen CH; Chen Y; Qin Q; Wang S; Wang C; Hu S; Li F; Long H; Brown M; Liu XS
Mol Cancer Res; 2016 Feb; 14(2):163-172. PubMed ID: 26659825
[TBL] [Abstract][Full Text] [Related]
18. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
19. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
[TBL] [Abstract][Full Text] [Related]
20. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
